2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.

Dec 10 (Reuters) - French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Can anything stop this high-flying drugmaker?

Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing ...

The pharmaceutical stock can still deliver.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.